Avastin, Tamiflu depress Roche sales by 7%

Poor performance from its cancer star Avastin and falloff from last year's pandemic sales of Tamiflu pushed Roche's sales down by 7 percent to $12.1 billion, below analysts' estimates; the company expects global pricing pressures to cut revenue growth by two percentage points this year. Article | Report